Pulmonx Corporation
LUNG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 22% | 28% | 10.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 74% | 73.9% | 74.3% | 73.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -60.6% | -80.2% | -104.3% | -96.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -67.3% | -88.6% | -109.8% | -100.5% |
| EPS Diluted | -1.44 | -1.6 | -1.59 | -1.35 |
| % Growth | 10% | -0.6% | -17.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |